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Background: Mycophenolate mofetil (MMF) is increasingly used to treat
primary glomerulopathies. Its effectiveness in IgA nephropathy (IgAN) remains
unclear. Methods: Forty IgAN patients with persistent proteinuria (> 1 g/24
hours) despite conventional treatment with blockers of the renin-angiotensin
system were randomized to receive MMF for 24 weeks (group 1) or continue
conventional therapy (group 2), and followed for 72 weeks. The primary end
point was reduction of proteinuria by 50% or more over entry level. Results:
Sixteen patients (80%) in group 1 versus 6 patients (30%) in group 2 reached
the primary end point (p = 0.0019). Time-averaged change in proteinuria showed
a significant decline in group 1, while control subjects displayed a modest rise
(p = 0.003). By 72 weeks, the mean proteinuria was 62.0 ( 7.7% (p = 0.003)
and 120.5 ( 14.1% (p = 0.351) that of the corresponding baseline value in
group 1 and group 2, respectively. There was a concomitant increase in serum
albumin and a decrease in serum IgA levels in group 1 but not group 2 patients.
Baseline histologic grades, blood pressure control, and the rates of change in
serum creatinine and creatinine clearance were not different between the two
groups. Normalization in binding of polymeric IgA to cultured mesangial cells
and serum interleukin-6 levels, which sustained to study end, was observed in
group 1 but not group 2 subjects. Conclusion: In selected patients with IgAN,
MMF is effective in lowering proteinuria and ameliorating some of the putative
pathogenetic abnormalities.
*Supported in part by the Hong Kong Society of Nephrology Research Grant
2002.
Lamivudine in Hepatitis B-associated Membranous Nephropathy
SCW Tang1,4, FMM Lai3, YH Lui5, CSO Tang1, NNS Kung4, YW Ho4,
KW Chan2, JCK Leung1, KN Lai1
Departments of 1Medicine and 2Pathology, The University of Hong Kong,
Queen Mary Hospital, Pokfulam; 3Department of Anatomical and Cellular
Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital,
Shatin; Departments of 4Medicine and Geriatrics and 5Tissue Pathology,
United Christian Hospital, Kwun Tong, Hong Kong SAR, China.
Background: Although lamivudine is effective for the treatment of chronic
hepatitis B (HBV) infection, its potential therapeutic impact on HBV-related
membranous nephropathy (MN) in adults has not been characterized. Methods:
We treated 10 HBsAg-positive patients with biopsy-proven MN, elevated serum
alanine aminotransferase (ALT), and HBV-DNAemia (group 1), and compared
their clinical course with 12 patients diagnosed to have HBV infection, elevated
serum ALT, and MN in the pre-lamivudine era (group 2). Results: Baseline
demographic and clinical parameters were not significantly different between
the 2 groups. In group 1, lamivudine treatment was associated with significant
reduction in proteinuria, increase in serum albumin, normalization of ALT levels
and disappearance of circulating HBV-DNA during the first year. Four (40%)
and six (60%) patients went into complete remission (proteinuria < 0.3 g/day)
at 6 and 12 months, respectively. In group 2, significant proteinuria persisted
during the first year. One (8.3%) and three (25%) patients went into remission.
Cumulative 3-year renal survival (using end-stage renal disease as the primary
end point) was 100% in group 1 and 58% in group 2 (p = 0.024, log rank test).
Blood pressure control reached the target of < 130/85 mmHg in both groups.
Lamivudine was well tolerated and not associated with any adverse events.
Hepatic decompensation or malignancy was not observed during follow up in
both groups. Conclusion: HBV-related MN led to end-stage renal disease in a
significant proportion of patients before the advent of anti-viral therapy.
Lamivudine treatment improves renal outcome in HBV carriers with MN and
evidence of liver disease.
Spironolactone Enhances Antiproteinuric Effect of Angiotensin-converting
Enzyme Inhibitor (ACEI)
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Background: It has been suggested that aldosterone may contribute to
progression of kidney disease. We attempted to investigate whether the
antiproteinuric effect of ACEI could be enhanced by co-administration of
spironolactone to antagonize the action of aldosterone. Methods: Twelve
patients (male:female, 5:7; mean age, 49 ( 7) on ACEI with refractory
proteinuria were studied. A fixed low dose of spironolactone (25 mg daily)
was added to the ACEI treatment. Patients were monitored for 8 weeks. Data
on serum potassium (K), serum albumin (Alb), proteinuria (Uprotein) and
creatinine clearance (CrCl) were collected. Wilcoxon’s signed rank test was
used for comparison of paired data. Results: The results (median, interquartile
range) are shown in the table below. All patients tolerated the treatment except
for one who developed hyperkalemia that required stopping of spironolactone.
A significant improvement in Alb and reduction in Uprotein were observed. A
transient decrease in CrCl was noted but there was no difference in CrCl values
between Week 0 and 8. There was no significant difference in blood pressure
during the study.
Week 0 Week 4 Week 8
K, mmol/L 4.1 (3.8–4.3) 4.4 (4.1–5.1) 4.1 (3.8–4.8)
Alb, g/L 33 (28–36)a 34 (31–37)b 36 (32–40)c
Uprotein, g/day 5.2 (4.0–8.8)
d 3.6 (2.3–8.1)e 1.6 (0.9–6.7)f
CrCl, mL/min 64.0 (53.0–91.3)g 43.5 (32.8–77.3)h 59.2 (42.4–89.1)
a vs b, a vs c, d vs f: p < 0.05; d vs e: p = 0.05; g vs h: p = 0.003.
Conclusion: Our findings suggest that the combination of ACEI and
spironolactone may exert an additive antiproteinuric effect. Patients should be
monitored closely for the development of hyperkalemia. Further study is
warranted to confirm the finding.
Preventing Extracorporeal Circuit Clotting in Hemodialysis –
A Comparison of Four Saline Flush Regimens
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Background: Intermittent saline flush is a strategy used to prevent
extracorporeal blood circuit clotting for hemodialysis (HD) without
anticoagulant. We compared four saline flush regimens to explore the effect of
flush volume and flush frequency on HD outcome, and to identify an effective
regimen with minimal flush frequency and volume of saline required. Methods:
Patients requiring heparin-free HD were recruited into the study. Each patient
had four sessions of standardized HD using four different flush regimens
arranged in a randomized sequence. The four regimens were: 100 mL every 15
minutes (Group A); 150 mL every 15 minutes (Group B); 200 mL every 15
minutes (Group C); and 200 mL every 30 minutes (Group D). Outcomes were
measured by effect on the HD procedure and the dialytic efficiency. Results:
Twelve patients with 48 HD procedures were studied. No patients had
coagulopathy. There were no differences among the groups with regard to
baseline Hct, Hb, platelet, PT, and APTT. Results showed no significant
differences for effect on the HD procedure and dialytic efficiency as assessed
by urea and creatinine reduction ratio among the four groups, although Group
D was shown to be slightly favorable.
Group A Group B Group C Group D p
Uneventful procedure 8 (67%) 8 (67%) 8 (67%) 9 (75%) NS
Required interruption 4 (33%) 4 (33%) 3 (25%) 3 (25%) NS
Failure to return blood 0 0 1 (8%) 0 NS
Time to interruption/
     failure (min)  162 ( 53  184 ( 29  189 ( 49  229 ( 3 NS
Urea reduction ratio (%) 59.9 ( 8.6 60.8 ( 7.0 60.5 ( 6.8 61.3 ( 7.1 NS
Creatinine reduction ratio (%) 55.3 ( 8.0 55.8 ( 6.4 56.3 ( 6.2 56.5 ( 5.8 NS
Conclusion: No significant differences on dialysis outcomes with the four flush
regimens were detected. Flushing with 200 mL saline every 30 minutes is
considered to be superior among the four regimens as it requires a lower flush
frequency and, thus, less nursing time and total saline required. Further study
with a larger sample size is recommended.
